Phase I/II ARROW study evaluated the activity of another RET inhibitor, pralsetinib (BLU-667), in RET+ solid cancers, including NSCLC (ClinicalTrials.gov Identifier: NCT03037385). The gene discussed is RET; the disease is non-small cell lung carcinoma.